(Q34752325)

4 August 2017

1 reference

title

Mechanisms and management of proarrhythmia (English)

1 reference

4 August 2017

Roden DM

1

1 reference

4 August 2017

language of work or name

English

0 references

publication date

1 August 1998

1 reference

American Journal of Cardiology

4 August 2017

published in

1 reference

4 August 2017

volume

82

1 reference

4 August 2017

issue

4A

1 reference

4 August 2017

page(s)

49I-57I

1 reference

Acute digitalis intoxication--is pacing still appropriate?

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900472-X

Digitalis. Mechanisms of action and clinical use.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900472-X

Autonomic influences in atrial tachyarrhythmias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900472-X

Antiarrhythmic agents: modulated receptor applications.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900472-X

Supraventricular tachycardia mimicking ventricular tachycardia during flecainide treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900472-X

Flecainide-induced ventricular tachycardia and fibrillation in patients treated for atrial fibrillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900472-X

Clinical and electrophysiologic assessment of oral flecainide acetate for recurrent ventricular tachycardia: evidence for exacerbation of electrical instability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900472-X

Malignant ventricular tachyarrhythmias associated with the use of encainide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900472-X

Flecainide: its proarrhythmic effect and expected changes on the surface electrocardiogram

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900472-X

Electrophysiological Effects of Flecainide on Anisotropic Conduction and Reentry in Infarcted Canine Hearts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900472-X

A reversal of the cardiotoxic effects of procaine amide by molar sodium lactate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900472-X

Acute electrophysiologic effects of sodium administration in dogs treated with O-desmethyl encainide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900472-X

Life-threatening flecainide toxicity. A pharmacodynamic approach

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900472-X

Amplification of flecainide-induced ventricular conduction slowing by exercise. A potentially significant clinical consequence of use-dependent sodium channel blockade

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900472-X

Reversal of proarrhythmic effects of flecainide acetate and encainide hydrochloride by propranolol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900472-X

Interactions between pharmacologic and nonpharmacologic antiarrhythmic therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900472-X

Evaluation of antiarrhythmic drugs on defibrillation energy requirements in dogs. Sodium channel block and action potential prolongation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900472-X

Effect of antiarrhythmic drugs on defibrillation threshold: case report of an adverse effect of mexiletine and review of the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900472-X

Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900472-X

Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900472-X

International mexiletine and placebo antiarrhythmic coronary trial: I. Report on arrhythmia and other findings. Impact Research Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900472-X

Oral disopyramide after admission to hospital with suspected acute myocardial infarction. U. K. Rythmodan Multicentre Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900472-X

Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900472-X

Alterations in regional myocardial distribution and arrhythmogenic effects of aprindine produced by coronary artery occlusion in the dog

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900472-X

QUINIDINE SYNCOPE. PAROXYSMAL VENTRICULAR FIBRILLATION OCCURRING DURING TREATMENT OF CHRONIC ATRIAL ARRHYTHMIAS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900472-X

Congenital deaf-mutism, functional heart disease with prolongation of the Q-T interval and sudden death

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900472-X

Proarrhythmia with class III antiarrhythmic drugs: definition, electrophysiologic mechanisms, incidence, predisposing factors, and clinical implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900472-X

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900472-X

Torsades de pointes and proarrhythmia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900472-X

Electrophysiologic mechanisms of the long QT interval syndromes and torsade de pointes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900472-X

N-Acetyl procainamide causing torsades de pointes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900472-X

Torsade de pointes induced by N-Acetylprocainamide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900472-X

Amiodarone and torsade de pointes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900472-X

Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900472-X

Clinical safety profile of sotalol in the treatment of arrhythmias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900472-X

Precordial QT interval dispersion as a marker of torsade de pointes. Disparate effects of class Ia antiarrhythmic drugs and amiodarone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900472-X

Proarrhythmic effects of the class III agent almokalant: importance of infusion rate, QT dispersion, and early afterdepolarisations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900472-X

Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900472-X

Action potential prolongation and induction of abnormal automaticity by low quinidine concentrations in canine Purkinje fibers. Relationship to potassium and cycle length.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900472-X

A canine model of torsades de pointes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900472-X

Cellular and Ionic Mechanisms Underlying Erythromycin-Induced Long QT Intervals and Torsade de Pointes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900472-X

Multiple mechanisms in the long-QT syndrome. Current knowledge, gaps, and future directions. The SADS Foundation Task Force on LQTS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900472-X

Cellular mechanisms of early afterdepolarizations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900472-X

Extracellular potassium modulation of drug block of IKr. Implications for torsade de pointes and reverse use-dependence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900472-X

Genetically defined therapy of inherited long-QT syndrome. Correction of abnormal repolarization by potassium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900472-X

Normalization of acquired QT prolongation in humans by intravenous potassium.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900472-X

Treatment of torsade de pointes with magnesium sulfate.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900472-X

Permanent cardiac pacing in patients with the long QT syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900472-X

Effects of verapamil and propranolol on early afterdepolarizations and ventricular arrhythmias induced by epinephrine in congenital long QT syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900472-X

Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900472-X

Limitations of routine long-term electrocardiographic monitoring to assess ventricular ectopic frequency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900472-X

10.1016/S0002-9149(98)00472-X

7 January 2021

Identifiers

DOI

1 reference

4 August 2017

1 reference